Rationale for clinical trials of coagulation: Reactive drugs in hepatocellular carcinoma

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 5, 2004, Pages 777-784

  Zacharski, Leo R ^a   Hommann, Merten ^b   Kaufmann, Roland ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Blood coagulation; Cancer; Heparin; Hepatocellular carcinoma; Urokinase

Indexed keywords

APROTININ; CANCER PROCOAGULANT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMIN; TANNIN; UROKINASE;

BLOOD CLOTTING; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOMA CELL; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; ENZYME INHIBITION; FIBRINOLYSIS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR CLASSIFICATION;

ANIMALS; ANTICOAGULANTS; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS; HEPARIN; HUMANS; LIVER NEOPLASMS; URINARY PLASMINOGEN ACTIVATOR;

EID: 4544349468     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.5.777     Document Type: Review

References (114)

1. Rickles FR, Levine MN, Dvorak HF. Abnormalities of hemostasis in malignancy. In: Hemostasis and Thrombosis. Basic Principles and Clinical Practice, Fourth Edition. Colman RW, Hirsh J, Marder VJ, Clowes AW, George JN (Eds), Lippincott Williams & Wilkins, PA, USA (2001).
2. Zacharski LR. Anticoagulants in cancer treatment malignancy as a solid-phase coagulopathy. Cancer Letts 186, 1-9 (2002).
3. Zacharski LR. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis and treatment of cancer. Semin. Thrombos. Hemostas. 29, 239-246 (2003).
4. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J. Natl Cancer Inst. 95, 1660-1673 (2003).
5. Wojtukiewicz MZ, Sierko E. Hemostasis and angiogenesis in malignancy. Semin. Thrombos. Hemostas. 30, 1-156 (2004).
6. Zacharski LP, Wojtukiewicz MZ, Costantini V, Ornstein DL, Memoli VA. Pathways of coagulation/fibrinolysis activation in malignancy. Semin. Thrombos. Hemostas. 18, 104-116 (1992).
7. Zacharski LR, Ornstein DL, Gabazza EC, D'Alessandro-Gabazza CN, Brugarolas A, Schneider J. Treatment of malignancy by activation of the plasminogen system. Semin. Thrombos. Hemostas. 28, 5-18 (2002).
8. Zacharski LR, Loynes JR, Ornstein DL, Rigas JR. The plasminogen system and cancer. Biomed. Prog. 15, 17-22 (2002).
9. Dunbar SD, Ornstein DL, Zacharski LR. Cancer treatment with inhibitors of urokinase-type plasminogen activator and plasmin. Exp. Opin. Invest. Drugs. 9(9), 2085-2092 (2000).
10. Francis JL, Amirkhosravi A. Effect of antihemostatic agents on experimental tumor dissemination. Semin. Thrombos. Hemostas. 28, 29-38 (2002).
11. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin and cancer. Chest 124(Suppl.3), S58-S68 (2003).
12. Poon RT, Lau CP, Ho JW, Yu WC, Fan ST, Wong J. Tissue factor expression correlates with tumor angiogenesis and invasiveness in human hepatocellular carcinoma. Clin. Cancer Res. 9, 5339-5345 (2003).
13. Zacharski LR, Morain WD, Schlaeppi J-M, Memoli VA, Rousseau SM. Cellular localization of enzymatically active thrombin in intact human tissue by hirudin binding. Thrombos. Haemostas. 73, 793-797 (1995).
14. Mann KG. Thrombin: can't live without it; probably die from it. Chest 124(Suppl. 1), S1-S3 (2003).
15. Trikha M, Nakada MT. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thrombos. Hemostas. 28, 39-44 (2002).
16. Zacharski LR, Ornstein DL. Heparin and cancer. Thrombos. Haemostas. 80, 10-23 (1998).
17. Varki NM, Varki A. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thrombos. Hemostas. 28, 53-66 (2002).
18. Liu D, Shriver Z, Qi Y, Venkataraman G, Sasisekharan R. Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin. Thrombos. Hemostas. 28, 67-78 (2002).
19. Nierodzik ML, Kajumo F, Karpatkin S. Effect of thrombin treatment of tumor cells on adhesion of tumor cells to platelets in vitro and tumor metastasis in vivo. Cancer Res. 52, 3267-3272 (1992).
20. Hollenberg MD, Compton SJ. International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Am 54, 203-217 (2002).
21. Kaufmann R, Schafberg H, Rudroff C, Nowak G. Thrombin receptor activation results in calcium signalling and PKC-dependent stimulation of DNA synthesis in Hep-2 laryngeal carcinoma cells. Cancer 80, 2068-2074 (1997).
22. Rudroff C, Schafberg H, Nowak G, Weinel R, Scheele J, Kaufmann R. Characterization of functional thrombin receptors in human pancreatic tumor cells (MIA PaCa-2). Pancreas 16, 189-194 (1998).
23. 6 cells. J. Neurosci. Res. 46, 641-651 (1996).
24. Schafberg H, Nowak G, Kaufmann R. Thrombin has a bimodal effect on glioma cell growth. Br. J. Cancer 76, 1592-1595 (1997).
25. Kaufmann R, Patt S, Schafberg H, Kalff R, Neupert G, Nowak G. Functional thrombin receptor PAR1 in primary cultures of human glioblastoma cells. Neuroreport 9, 709-712 (1998).
26. Zieger M, Tausch S, Henklein P, Nowak G, Kaufmann R. A novel PAR-I-type thrombin receptor signaling pathway: cyclic AMP-independent activation of PKA in SNB-19 glioblastoma cells. Biochem. Biophys. Res. Commun. 282, 952-957 (2001).
27. Kaufmann R, Patt S, Kraft R, Zieger M, Neupert G, Nowak G. PAR1-type thrombin receptors are involved in thrombin-induced calcium signaling in human meningioma cells. J. Neurooncol. 42, 131-136 (1999).
28. Chay CH, Cooper CR, Gendernalik JD et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 60, 760-765 (2002).
29. Liu J, Bastian M, Kohlschein P, Schuff-Werner P, Steiner M. Expression of functional protease-activated receptor 1 in human prostate cancer cell lines. Urol. Res. 31, 163-168 (2003).
30. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am. J. Pathol. 162, 1503-1513 (2003).
31. Kaufmann R, Junker U, Nuske K et al. PAR-1- and PAR-3-type thrombin receptor expression in primary cultures of human renal cell carcinoma cells. Int. J. Oncol. 20, 177-180 (2002).
32. Fong Y, Kemeny N, Lawrence TS. Cancer of the liver and biliary tree. In: Cancer: Principles and Practice of Oncology, Sixth Edition. DeVita VT, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, PA, USA (2001).
33. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003).
34. Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 39, 109-118 (2001).
35. Coleman WB. Mechanisms of human hepatocarcinogenesis. Curr. Mol. Med. 3, 573-588 (2003).
36. Putterman D, Safadi R, Ilan Y, Rivkind AI, Ben-Chetrit E. Pulmonary embolism as the presenting feature of hepatocellular carcinoma. Presse Med. 23, 474-476 (1994).
37. Schoniger-Hekele M, Muller C, Kutilek M, Oesterreicher C, Ferenci P, Gangl A. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut 48, 103-109 (2001).
38. Wallace MJ. Transatrial stent placement for treatment of inferior vena cava obstruction secondary to extension of intracardiac tumor thrombus from hepatocellular carcinoma. J. Vasc. Interv. Radiol. 14, 1339-1343 (2003).
39. Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am. J. Gastroenterol. 98, 201-204 (2003).
40. Luo JC, Hwang SJ, Wu JC et al. Clinical characteristics and prognosis of hepatocellular carcinoma patients with paraneoplastic syndromes. Hepatogastroenterology 49, 1315-1319 (2002).
41. Shirabe K, Shimada M, Tsujita E et al. Thrombectomy before hepatic resection for hepatocellular carcinoma with a tumor thrombus extending to the inferior vena cava. Int. Surg. 86, 141-143 (2001).
42. Kojima Y, Suzuki S, Sakaguchi T et al. Portal vein thrombosis caused by microwave coagulation therapy for hepatocellular carcinoma: report of a case. Surg. Today 30, 844-848 (2000).
43. Seki S, Yamada T, Kawakita N, Masuichi H, Kitada T, Sakaguchi H. A new chemotherapeutic regimen for advanced unresectable hepatocellular carcinoma. Hepatogastroenterology 50, 1598-1602 (2003).
44. Dewey WC, Bale WF, Rose RG, Marrack D. Localization of antifibrin antibodies in human tumors. Acta Unio. Int. Contra Cancrum. 19, 185-196 (1963).
45. Colombo M, Sangiovanni A. Etiology, natural history and treatment of hepatocellular carcinoma. Antiviral Res. 60, 145-150 (2003).
46. Velazquez RF, Rodriguez M, Navascues CA et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37, 520-527 (2003).
47. Lefrere JJ, Conard J, Mavier P et al. Coagulation assays as diagnostic markers of hepatocelllar carcinoma. Thrombos. Haemostas. 60, 468-470 (1988).
48. Miatto O, Casaril M, Gabrielli GB, Nicoli N, Bellisola G, Corrocher R. Diagnostic and prognostic value of serum copper and plasma fibrinogen in hepatic carcinoma. Cancer 55, 774-778 (1985).
49. Tomiya T, Fujiwara K. Plasma thrombin-antithrombin III complexes in the diagnosis of primary hepatocellular carcinoma complicating liver cirrhosis. Cancer 67, 481-485 (1991).
50. Kruskal JB, Robson SC, Franks JJ, Kirsch RE. Elevated fibrin-related and fibrinogen-related antigens in patients with liver disease. Hepatology 16, 920-923 (1992).
51. Kim HK, Lee KR, Yang JH et al. Plasma levels of D-dimer and soluble fibrin polymer in patients with hepatocellular carcinoma: a possible predictor of tumor thrombosis. Thrombos. Res. 109, 125-129 (2003).
52. van der Walt JA, Gomperts ED, Kew MC. Hemostatic factors in primary hepatocellular cancer. Cancer 40, 1593-1603 (1977).
53. Kwaan HC, Lo R, McFadzean AJ. Antifibrinolytic activity in primary carcinoma of the liver. Clin. Sci. 18, 251-261 (1959).
54. Furukawa M, Nakanishi T, Okuda H, Ishida S, Obata H. Changes of plasma des-γ-carboxy prothrombin levels in patients with hepatocellular carcinoma in response to vitamin K. Cancer 69, 31-38 (1992).
55. Tagawa M, Omata M, Ohto M. Nucleotide sequence of prothrombin gene in abnormal prothrombin-producing hepatocellular carcinoma cell lines. Cancer 69, 643-647 (1992).
56. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. Br. J. Haematol. 114, 249-257 (2001).
57. Leone G, De Stefano V, Garufi C, Ferrelli R, Cassano A, Grieco A. Antithrombin III in patients with hepatocellular carcinoma. Thrombos. Haemostas. 58, 1093 (1987).
58. Wages DS, Staprans I, Hambleton J, Bass NM, Corash L. Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma. Am. J. Hematol. 58, 285-292 (1998).
59. Messmore HL, Griffin B, Fareed J, Orfei E. Acquired von Willebrand disease due to hyluronic acid produced by a hepatoma. Blood. 90(Suppl. 1, Pt 2), 303a (1997) (Abstract 1123).
60. Neaud V, Hisaka T, Monvoisin A et al. Paradoxical proinvasive effect of the serine proteinase inhibitor tissue factor pathway inhibitor-2 on human hepatocellular carcinoma cells. J. Biol. Chem. 275, 35565-35569 (2000).
61. Sakai T, Kisiel W. Binding of human factors X and Xa to HepG2 and J82 human tumor cell lines. Evidence that Factor Xa binds to tumor cells independent of Factor Va. J. Biol. Chem. 265, 9105-9113 (1990).
62. Suehiro T, Shimada M, Matsumata T, Taketomi A, Yamamoto K, Sugimachi K. Thrombomodulin inhibits intrahepatic spread in human hepatocellular carcinoma. Hepatology 21, 1285-1290 (1995).
63. Karti SS, Ovali E, Ozgur O et al. Induction of apoptosis and inhibition of growth of human hepatoma HepG2 cells by heparin. Hepatogastroenterology 50, 1864-1866 (2003).
64. Tang Z, Zhou X, Lin Z et al. Surgical treatment of hepatocellular carcinoma and related basic research with special reference to recurrence and metastasis. Chin. Med. J. (Engl). 112, 887-891 (1999).
65. Ko FN, Yu SM, Teng CM. Protracted treatment with phorbol ester modulates J-7 human hepatoma-cell-induced aggregation and coagulation of human platelet-rich plasma. Int. J. Cancer 59(5), 706-711 (1994).
66. Yu Y, Zhou XD, Liu YK, Ren N, Chen J, Zhao Y. Platelets promote the adhesion of human hepatoma cells with a highly metastatic potential to extracellular matrix protein: involvement of platelet P-selectin and GP Ilb-IIIa. J. Cancer Res. Clin. Oncol. 128, 283-287 (2002).
67. Pikas DS, Li JP, Vlodavsky I, Lindahl U. Substrate specificity of heparanases from human hepatoma and platelets. J. Biol. Chem. 273, 18770-18777 (1998).
68. Barbour AP, Reeder JA, Walsh MD, Fawcett J, Antalis TM, Gotley DC. Expression of the CD44v2-10 isoform confers a metastatic phenotype: importance of the heparan sulfate attachment site CD44v. Cancer Res. 63, 887-892 (2003).
69. Hiyoshi M, Ohkubo T, Tsuji K et al. Hepatocyte proliferation factors from neonatal pig liver: purification and characterization. Biofactors 16, 1-14 (2002).
70. Yoshida K, Nakamura H, Okuda Y et al. Expression of hepatoma-derived growth factor in hepatocarcinogenesis. J. Gastroenterol. Hepatol. 18, 1293-1301 (2003).
71. Dietz F, Franken S, Yoshida K, Nakamura H, Kappler J, Gieselmann V. The family of hepatoma-derived growth factor proteins: characterization of a new member HRP-4 and classification of its subfamilies. Biochem. J. 366, 491-500 (2002).
72. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V, Franken S. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem. J. 378, 169-176 (2004).
73. Roth-Eichhorn S, Heitmann B, Flemming P, Kubicka S, Trautwein C. Evidence for the decreased expression of the latent TGF-β binding protein and its splice form in human liver tumours. Scand. J. Gastroenterol. 36, 1204-1210 (2001).
74. Ito Y, Takeda T, Higashiyama S et al. Expression of heparin-binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol. Rep. 8, 903-907 (2001).
75. Akiba J, Yano H, Ogasawara S, Higaki K, Kojiro M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int. J. Oncol. 18, 257-264 (2001).
76. Ikematsu S, Yano A, Aridome K et al. Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer 83, 701-706 (2000).
77. Kato M, Shinozawa T, Kato S, Awaya A, Terada T. Increased midkine expression in hepatocellular carcinoma. Arch. Pathol. Lab. Med. 124, 848-852 (2000).
78. Kiso S, Kawata S, Tamura S et al. Expression of heparin-binding epidermal growth factor-like growth factor in the hepatocytes of fibrotic rat liver during hepatocarcinogenesis. J. Gastroenterol. Hepatol. 14, 1203-1209 (1999).
79. Hisaka T, Yano H, Haramaki M, Utsunomiya I, Kojiro M. Expressions of epidermal growth factor family and its receptor in hepatocellular carcinoma cell lines: relationship to cell proliferation. Int. J. Oncol. 14, 453-460 (1999).
80. Ito N, Higashiyama S, Kawata S et al. Regulation of heparin-binding EGF-like growth factor expression by phorbol ester in a human hepatoma-derived cell line. Biochem. Biophys. Acta 1310, 163-167 (1996).
81. Miyoshi E, Higashiyama S, Nakagawa T et al. High expression of heparin-binding EGF-like growth factor in rat hepatocarcinogenesis. Int. J. Cancer 68, 215-218 (1996).
82. Inui Y, Higashiyama S, Kawata S et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 107, 1799-1804 (1994).
83. Ishikawa H, Nakata K, Tsuruta S et al. Differential regulation of albumin gene expression by heparin-binding epidermal growth factor like growth factor in α-fetoprotein-producing and -nonproducing human hepatoma cells. Tumour Biol. 20, 130-138 (1999).
84. Dudas J, Ramadori G, Knittel T et al. Effect of heparin and liver heparan sulfate on interaction of HepG2-derived transcription factors and their cis-acting elements: altered potential of hepatocellular carcinoma heparan sulfate. Biochem. J. 350, 245-251 (2000).
85. Hardy RW, Marcotrigiano J, Blot KJ, Majors JE, Rice CM. Hepatitis C virus RNA synthesis in a cell-free system isolated from replicon-containing hepatoma cells. J. Virol. 77, 2029-2037 (2003).
86. Lai JP, Chien JR, Moser DR et al. hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterelogy 126, 231-248 (2004).
87. Matsumoto A, Ono M, Fujimoto Y, Gallo RL, Bernfield M, Kohgo Y. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int. J. Cancer 74, 482-491 (1997).
88. Kirchheimer JC, Huber K, Polterauer P, Binder BR. Urokinase antigen in plasma of patients with liver cirrhosis and hepatoma. Thromb. Haemostas. 54, 617-618 (1985).
89. Huber K, Kirchheimer JC, Ermler D, Bell C, Binder BR. Determination of plasma urokinase-type plasminogen activator in patients with primary liver cancer: characterization as tumor-associated antigen and comparison with α-fetoprotein. Cancer Res. 52, 1717-1720 (1992 ).
90. Tavian D, Salvi A, De Petro G, Barlati S. Stable expression of antisense urokinase mRNA inhibits the proliferation and invasion of human hepatocellular carcinoma cells. Cancer Gene Ther. 10, 112-120 (2003).
91. Tavian D, De Petro G, Benetti A, Portolani N, Giulini SM, Barlati S. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is downregulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644-649 (2000).
92. De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor and tissue-type PA messenger RNAs in human hepatocellular carcinoma. Cancer Res. 58, 2234-2239 (1998).
93. Zhou L, Hayashi Y, Itoh T, Wang W, Rui J, Itoh H. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitor-1 and -2 in hepatocellular carcinoma. Pathol. Int. 50, 392-397 (2000).
94. Dubuisson L, Monvoisin A, Nielsen BS, Le Bail B, Bioulac-Sage P, Rosenbaum J. Expression and cellular localization of the urokinase-type plasminogen activator and its receptor in human hepatocellular carcinoma. J. Pathol. 190, 190-195 (2000).
95. Akahane T, Ishii M, Ohtani H, Nagura H, Toyota T. Stromal expression of urokinase-type plasminogen activator receptor (uPAR) is associated with invasive growth in primary liver cancer. Liver 18, 414-419 (1998).
96. Itoh T, Hayashi Y, Kanamaru T et al. Clinical significance of urokinase-type plasminogen activator activity in hepatocellular carcinoma. J. Gastroenterol. Hepatol. 15, 422-430 (2000).
97. Monvoisin A, Neaud V, De Ledinghen V et al. Direct evidence that hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells is mediated by urokinase. J. Hepatol. 30, 511-518 (1999).
98. Tian J, Tang ZY, Ye SL et al. New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br. J. Cancer 81, 814-821 (1999).
99. Arndt A, Murphy P, Hart DA. Human HuH-7 hepatoma cells express urokinase and plasminogen activator inhibitor-1: identification, characterization and regulation by inflammatory mediators. Biochem. Biophys. Acta. 1138, 149-156 (1992).
100. Murakami E, Sakukawa R, Ikeda T et al. Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase. Neoplasia 1, 424-430 (1999).
101. Morita Y, Hayashi Y, Wang Y et al. Expression of urokinase-type plasminogen activator receptor in hepatocellular carcinoma. Hepatology 25, 856-861 (1997).
102. Morita Y, Hayashi Y, Kanamaru T et al. Inhibitory role of plasminogen activator inhibitor-1 in invasion and proliferation of HLE hepatocellular carcinoma cells. Jpn J. Cancer Res. 90, 747-752 (1999).
103. Nieto-Rodriguez A, Hernandez-Pando R, Kershenobich D, Rodriguez-Fragoso L. Expression of urokinase-type plasminogen activator in an experimental model of hepatocarcinoma. Toxicology 161, 13-23 (2001).
104. Zheng Q, Tang ZY, Xue Q, Shi DR, Song HY, Tang HB. Invasion and metastasis of hepatocellular carcinoma in relation to urokinase-type plasminogen activator, its receptor and inhibitor. J. Cancer Res. Clin. Oncol. 126, 641-646 (2000).
105. Taitzoglou IA, Tsantarliotou MP, Nepka C et al. Dietary administration of tannic acid lowers plasminogen activator activity in the liver of C3H hepatoma-bearing male mice. In Vivo 14, 767-771 (2000).
106. Schoedel KE, Tyner VZ, Kim TH, Michalopoulos GK, Mars WM. HGF, MET and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver. Mod. Pathol. 16, 14-21 (2003).
107. Tacchini L, Dansi P, Matteucci E, Desiderio MA. Hepatocyte growth factor signalling stimulates hypoxia inducible factor-1 (HIF-1) activity in HepG2 hepatoma cells. Carcinogenesis 22, 1363-1371 (2001).
108. Wojta J, Nakamura T, Fabry A et al. Hepatocyte growth factor stimulates expression of plasminogen activator inhibitor Type 1 and tissue factor in HepG2 cells. Blood 84, 151-157 (1994).
109. Kamiyama T, Une Y, Uchino J, Hamada J. Hepatocyte growth factor enhances the invasion activity of human hepatocellular carcinoma cell lines. Int. J. Oncol. 12, 655-659 (1998).
110. DeLedinghen V, Monvoisin A, Neaud V et al. Trans-resveratrol, a grapevine-derived polyphenol, blocks hepatocyte growth factor-induced invasion of hepatocellular carcinoma cells. Int. J. Oncol. 19, 83-88 (2001).
111. Lee SJ, Ohashi Y, Sakurai H, Saiki I. TAC-101 inhibit, intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. Cancer Letts 20, 198, 169-177 (2003).
112. Umezawa K. Inhibition of experimental metastasis by enzyme inhibitors from microorganisms and plants. Adv. Enzyme Regul. 36, 267-281 (1996).
113. Putnam JB, Royston D, Chambers AF et al. Evaluating the role of serine protease inhibition in the management of tumor micrometastases. Oncology 17(Suppl. 10), 9-30 (2003).
114. Yoshitomi Y, Nakanishi H, Kusano Y et al. Inhibition of experimental lung metastases of Lewis lung carcinoma cells by chemically modified heparin with reduced anticoagulant activity. Cancer Letts 207, 165-74 (2004).